co
in-lin pre-announce
difficult comp expect
tuesday share trade vs follow releas
result in-lin pre-announce januari
attribut stock weak lower-than-consensu sale ep guidanc
make year back-end load net/net wasnt anyth prompt
rethink stock continu see modest upsid potenti share
enough warrant posit stanc rate share equal weight
continu believ consensu ep estim could prove bit high
given move part includ end gore royalti
key takeaway quarter call convers
expect street bd expect compar fx neutral sale
growth around low end full year rang
around driven tough flu comparison time pharma system
net puts/tak ep also expect lower
consensu given sale outlook fx impact time spend well higher
tax rate bd remain confid abil achiev full year goal
bd believ continu take share infus pump dispens system
bd also re-affirmed revenu cost synergi expect bard
takeaway call see call note publish feb click
weve updat model reflect recent quarter manag
commentari outlook view achiev result
net/net ep estim fairli unchang estim
maintain price target
appli multipl calendar ep estim
quarterli annual ep usd
consensu number refinitiv receiv gmt
barclay capit inc and/or one affili seek busi
compani cover research report result investor awar
firm may conflict interest could affect object report investor
consid report singl factor make invest decis
return equiti ttm
link barclay live interact chart
barclay co
co
margin return data
balanc sheet cash flow mn
equival
short long-term debt
chang work capit
flow oper
valuat leverag metric
equal weight believ bd
success integr bard achiev plan
synergi though market alreadi appreci
base success integr carefus
ep recalibr think
street forecast may still high
see upsid near-term enough
warrant chang view rate ew
upsid case could driven better-than-
bard acquisit improv overal
growth rate higher earn
downsid case could driven foreign
exchang stronger us dollar could pressur
expect sale legaci bard busi
slowdown emerg market growth
inabl off-set gore royalti
barclay co
becton pre-announce sale ep in-lin pre-announce
pre-announc consensu estim compar constant currenc growth
balanc perform across three busi unit ep
better expect driven mainli lower tax rate time discret item
well better sale gross margin earli januari bd manag comment
expect ep low bd provid explicit guidanc
street/our expect re-affirmed full year target net/net view
rel unchang continu see bd steadi compound growth stori
see upsid potenti howev concern around expect
leav us bit sidelin rate share equal weight
addit detail quarter
million except per share data chang sale constant currenc organ basi unless otherwis note
deliv compar constant currenc growth due strong infus
capit placement continu market share gain infus pump
pyxi
pharmaceut system due strong demand core product
surgeri due favor comp due hurrican maria within
hernia busi well benefit reintroduct progel
sale ep guidanc street expect ep guidanc
well street estim
medic deliveri solut md peripher intervent pi sale
weaker we/street expect management note in-lin
expect md grew fx neutral compar basi due tough
comp pi due tough comp includ termin distribut
agreement management note safeti concern impact drug-coat balloon sale
sale report basi compar
constant currenc basi growth broad-bas intervent
medic life scienc
gross margin y/i expect
model reflect inclus bard continu improv cost synergi
favor mix off-set fx headwind
sg sale y/i reflect bard higher spend profil
partial off-set synergi
 sale y/i bd continu invest innov
oper margin y/i driven gross margin improv
synergi captur fx neg impact oper margin
adjust tax rate y/i guidanc
rang due time discret item
adjust ep includ fx headwind
bd manag expect revenu growth full year guidanc rang larg due tough flu
comp time within pharm system net put take ep expect addit
headwind fx ep growth impact lower revenu growth raw materi divestitur time expens
tax rate expect full year rate
bd continu expect report sale growth constant currenc compar sale growth
reflect bd medic growth lifesci intervent bd reiter ep guidanc
actualsal mrptdc-fxnbd management compar fx neutral basisyoy changebd barclay co
abbrevi model million except per share data
compani report barclay research
statementtot inc exp stock inc share incom barclay co
kristen stewart cfa herebi certifi view express research report accur reflect person view
subject secur issuer refer research report part compens directli indirectli
relat specif recommend view express research report
